These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31866629)

  • 1. Long-term Successful Treatment of Rituximab for Steroid-resistant Minimal Change Nephrotic Syndrome and Idiopathic Thrombocytopenic Purpura.
    Nishikawa M; Shimada N; Kawazoe T; Sawaki R; Ikuta H; Kanzaki M; Fukuoka K; Fukushima M; Asano K
    Intern Med; 2020 Apr; 59(7):983-986. PubMed ID: 31866629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.
    Koulova L; Alexandrescu D; Dutcher JP; O'Boyle KP; Eapen S; Wiernik PH
    Am J Hematol; 2005 Jan; 78(1):49-54. PubMed ID: 15609292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of adding rituximab to splenectomy and romiplostim for treating steroid-resistant idiopathic thrombocytopenic purpura in adults.
    Kikuchi K; Miyakawa Y; Ikeda S; Sato Y; Takebayashi T
    BMC Health Serv Res; 2015 Jan; 15():2. PubMed ID: 25609557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case of minimal change nephrotic syndrome complicated by Kimura disease treated with rituximab.
    Yoshida R; Hara Y; Fujii Y; Matuda H
    CEN Case Rep; 2023 Nov; 12(4):368-373. PubMed ID: 36809634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Children with Persistent and Chronic Idiopathic Thrombocytopenic Purpura: 4 Infusions of Rituximab and Three 4-Day Cycles of Dexamethasone.
    Oved JH; Lee CSY; Bussel JB
    J Pediatr; 2017 Dec; 191():225-231. PubMed ID: 29173312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective single-arm cohort study of steroid-dependent minimal change nephrotic syndrome treated with very low-dose rituximab.
    Fujimoto K; Kagaya Y; Kumano S; Fujii A; Tsuruyama Y; Matsuura T; Yamazaki K; Nomura K; Okada K; Okino K; Adachi H; Furuichi K; Yokoyama H
    Clin Nephrol; 2021 Jan; 95(1):29-36. PubMed ID: 33074094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is splenectomy necessary for immune thrombocytopenic purpura? The role of rituximab in patients with corticosteroid resistance in a single-center experience.
    Zhang C; Liu HF; Chen XH; Gao L; Gao L; Liu Y; Kong PY; Sun AH; Zhang X
    Clin Ther; 2014 Mar; 36(3):385-8. PubMed ID: 24594069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Splenectomy vs. rituximab as a second-line therapy in immune thrombocytopenic purpura: a single center experience.
    Al Askar AS; Shaheen NA; Al Zahrani M; Al Otaibi MG; Al Qahtani BS; Ahmed F; Al Zughaibi M; Kamran I; Mendoza MA; Khan A
    Int J Hematol; 2018 Jan; 107(1):69-74. PubMed ID: 28895035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy.
    Benz K; Dötsch J; Rascher W; Stachel D
    Pediatr Nephrol; 2004 Jul; 19(7):794-7. PubMed ID: 15071769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective analysis of rituximab therapy and splenectomy in childhood chronic and refractory immune thrombocytopenic purpura.
    Ay Y; Karapinar TH; Oymak Y; Toret E; Demirag B; Ince D; Ozcan E; Moueminoglou N; Koker SA; Vergin C
    Blood Coagul Fibrinolysis; 2016 Jun; 27(4):431-5. PubMed ID: 26656905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
    Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
    Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab therapy for steroid-dependent minimal change nephrotic syndrome.
    Gilbert RD; Hulse E; Rigden S
    Pediatr Nephrol; 2006 Nov; 21(11):1698-700. PubMed ID: 16932900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome.
    Shanafelt TD; Madueme HL; Wolf RC; Tefferi A
    Mayo Clin Proc; 2003 Nov; 78(11):1340-6. PubMed ID: 14601692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results.
    Medeot M; Zaja F; Vianelli N; Battista M; Baccarani M; Patriarca F; Soldano F; Isola M; De Luca S; Fanin R
    Eur J Haematol; 2008 Sep; 81(3):165-9. PubMed ID: 18510702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent minimal change nephrotic syndrome and type 1 diabetes mellitus in an adult Japanese woman: a case report.
    Nishizono R; Kogou H; Ishizaki Y; Minakawa A; Kikuchi M; Inagaki H; Sato Y; Fujimoto S
    BMC Nephrol; 2020 Sep; 21(1):410. PubMed ID: 32967631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of Fc gamma receptor IIa and IIIa gene polymorphisms on the therapeutic response of rituximab in Egyptian adult immune thrombocytopenic purpura.
    Ellithy HN; Ahmed SH; Shahin GH; Matter MM; Talatt M
    Hematology; 2018 Apr; 23(3):169-174. PubMed ID: 28856973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab for Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome in Adults: A Retrospective, Multicenter Study in Spain.
    DaSilva I; Huerta A; Quintana L; Redondo B; Iglesias E; Draibe J; Praga M; Ballarín J; Díaz-Encarnación M;
    BioDrugs; 2017 Jun; 31(3):239-249. PubMed ID: 28534103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment with rituximab of refractory idiopathic thrombocytopenic purpura in a patient with Kabuki syndrome.
    Torii Y; Yagasaki H; Tanaka H; Mizuno S; Nishio N; Muramatsu H; Hama A; Takahashi Y; Kojima S
    Int J Hematol; 2009 Sep; 90(2):174-176. PubMed ID: 19662467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab.
    Kamei K; Ishikura K; Sako M; Aya K; Tanaka R; Nozu K; Kaito H; Nakanishi K; Ohtomo Y; Miura K; Takahashi S; Morimoto T; Kubota W; Ito S; Nakamura H; Iijima K;
    Pediatr Nephrol; 2017 Nov; 32(11):2071-2078. PubMed ID: 28664242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab in the treatment of relapsing idiopathic thrombocytopenic purpura.
    Riksen NP; Keuning JJ; Vreugdenhil G
    Neth J Med; 2003 Jul; 61(7):262-5. PubMed ID: 14567524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.